Novartis and Ratio Enter Radiotherapeutics Partnership Worth $745m
Novartis and Ratio Therapeutics have entered into a worldwide licence and collaboration agreement worth $745m to advance a somatostatin receptor 2 (SSTR2)-targeting ...
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative